Relationship between 17β estradiol (17βE) levels and Catechol-O-methyltransferase (COMT) levels in ovarian cancers

Nour M El-Etreby, Nehal A El Badawy, Hoda A Nour, Eman M Osman

1 Department of Obstetrics and Gynecology, Faculty of Medicine, Alexandria University, 21526 Alexandria, Egypt
2 Department of Pathology, Medical Research Institute, Alexandria University, 21526 Alexandria, Egypt
3 Department of Physiology, Medical Research Institute, Alexandria University, 21526 Alexandria, Egypt
4 Department of Immunology and Allergy, Medical Research Institute, Alexandria University, 21561 Alexandria, Egypt

*Correspondence: eman.immunology@gmail.com (Eman M Osman)

DOI: 10.31083/j.ejgo4204114

This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).

Submitted: 24 December 2020 Revised: 27 January 2021 Accepted: 17 February 2021 Published: 15 August 2021

Objectives: Epidemiological data show that induction of ovarian cancer is related to estrogen exposure and metabolism. In addition, catechol metabolites of estrogen also contribute to carcinogenesis. O-methylation by Catechol-O-methyltransferase is a phase II metabolic inactivation pathway for catechol estrogens. The goal of this study was to evaluate a potential correlation between COMT and 17β estradiol levels and ovarian cancer. Subjects and methods: COMT and 17βE levels were measured in ovarian tissue and serum from 80 subjects: 30 with malignant ovarian tumors, 30 with benign ovarian tumors and 20 healthy controls. Results: Tissue and serum levels of Catechol-O-methyltransferase and 17β estradiol were determined using enzyme linked immunosorbant assay. According to our results Catechol-O-methyltransferase inhibition in the malignant group was associated with high levels of 17β estradiol, while in benign group high levels of COMT was associated with low levels of 17β estradiol in both serum and tissue homogenates. Conclusions: Low level of COMT and high tissue/serum levels of 17β estradiol may be contributory factors for the development of ovarian cancer. This supports the notion that targeting the metabolism of estrogen can be another way to reduce ovarian cancer risk.

Keywords
Ovarian cancer, Catechol-O-methyltransferase, 17β estradiol (E2)

1. Introduction

During reproductive years, granulosa cells secrete both estradiol (E2) and estrone (E1) after stimulation of the sex steroid hormone synthesis in the ovary [1]. After menopause, estrogens are formed locally in various tissues. Estradiol is produced by circulating androgen and estrogen precursors and transported to ovarian epithelial cells [2]. Previous studies have demonstrated that 17β estradiol, its interconvertible metabolite estrone and their catechol metabolites are carcinogenic [2, 3]. Oxidative metabolism of estradiol/estrone to catechols involves reactive metabolites formation, generating mutagenic DNA adducts. Free radicals from estrogen metabolic activation cause mutations, and their accumulation lead to neoplastic transformation of proliferating cells [3–7].
Table 1. Comparison between the three studied groups according to Catechol-O-methyl transferase.

|                  | Control (n = 20) | Benign (n = 30) | Malignant (n = 30) | H   | p       |
|------------------|------------------|-----------------|-------------------|-----|---------|
| COMT tissue      | 529.55 ± 77.89   | 650.97 ± 130.32 | 386.50 ± 96.47    | 46.968* | <0.00* |
| Significance     | p1: 0.039, p2: 0.001*, p3: 0.001* |                   |                   |     |         |
| COMT serum       | 323.40 ± 18.30   | 475.20 ± 214.34 | 367.70 ± 80.64    | 28.752* | <0.00* |
| Significance     | p1: 0.001*, p2: 0.022*, p3: 0.001* |                   |                   |     |         |
| Tissue vs. serum | <0.001*          | <0.001*         | 0.028*            |     |         |
| Ratio tissue/serum| 1.65 ± 0.32     | 1.50 ± 0.38     | 1.06 ± 0.18       | 35.420* | <0.00* |
| Significance     | p1: 0.289, p2: 0.001*, p3: 0.001* |                   |                   |     |         |

H, H for Kruskal Wallis test, Pairwise comparison bet. Each 2 groups was done using Post Hoc Test (Dunn’s for multiple comparisons test). p: p value for comparing between the studied groups. p1: p value for comparing between Control and Benign. p2: p value for comparing between Control and Malignant. p3: p value for comparing between Benign and Malignant.

*, Statistically significant at p ≤ 0.05.

Table 2. Comparison between the three studied groups according to 17β estradiol.

|                  | Control (n = 20) | Benign (n = 30) | Malignant (n = 30) | H   | p       |
|------------------|------------------|-----------------|-------------------|-----|---------|
| 17β estradiol tissue | 11.35 ± 0.71      | 15.20 ± 1.44     | 21.18 ± 5.50      | 65.312* | <0.00* |
| Significance     | p1: 0.001*, p2: 0.001*, p3: 0.001* |                   |                   |     |         |
| 17β estradiol serum | 8.71 ± 1.12       | 9.90 ± 1.96      | 13.46 ± 4.90      | 23.450* | <0.00* |
| Significance     | p1: 0.034*, p2: 0.001*, p3: 0.003* |                   |                   |     |         |
| Tissue vs. serum | <0.001*           | <0.001*         | <0.001*           |     |         |
| Tissue/serum ratio | 1.33 ± 0.24      | 1.57 ± 0.22      | 1.73 ± 0.62       | 7.995* | 0.018* |
| Significance     | p1: 0.020*, p2: 0.007*, p3: 0.673 |                   |                   |     |         |

H, H for Kruskal Wallis test, Pairwise comparison bet. Each 2 groups was done using Post Hoc Test (Dunn’s for multiple comparisons test). p: p value for comparing between the studied groups. p1: p value for comparing between Control and Benign. p2: p value for comparing between Control and Malignant. p3: p value for comparing between Benign and Malignant.

*, Statistically significant at p ≤ 0.05.

2.1 Methods

2.1.1 Sample collection

Tissues of normal ovaries and ovarian carcinomas were frozen in Roswell Park Memorial Institute (RPMI) media and stored at −80 °C. Before analysis, ovarian tissues were homogenized in the media to obtain tissue homogenates.

For serum samples, five mL of blood was obtained and centrifuged at 3000 rpm for 10 minutes.

Both COMT and 17β estradiol levels were determined in serum samples and tissue homogenates using enzyme-linked immunosorbent assay (ELISA) from E bioseps (SNF Medical). The assays were performed in duplicate according to the manufacturer’s protocols.

2.1.2 Determination of COMT and 17β estradiol levels by ELISA

In brief, standards, test samples and control wells were set on pre-coated 96-well ELISA plates with captured antibodies (anti-Catechol-O-methyltransferase antibodies for COMT and anti 17β estradiol antibodies for 17β estradiol). Duplicate aliquots (50 µL per well) of diluted sera and different standard protein concentrations were loaded onto the ELISA plate. The plates were then incubated for 30 min at 37 °C. Unbound materials were washed out, and biotinylated secondary antibodies (anti-Catechol-O-methyltransferase and anti 17β estradiol) were added to each well. The plates were incubated for 30 min at 37 °C. After extensive washing, color development was performed by incubation with horseradish peroxidase substrate (substrate A and substrate B). After adding stop solution, the optical density (O.D.) at 450 nm was determined for each well using a microplate reader, and the concentrations of samples were determined by comparison to the standard concentration curves.

2.2 Statistical analysis

Data were fed to the computer and analyzed by IBM SPSS software package version 20.0. (IBM Corp, Armonk, NY, USA). The Kolmogorov-Smirnov test was used to verify the normality of distribution of variables, and comparisons between groups for categorical variables were assessed by Chi-square test. Mann-Whitney test was utilized to compare two groups for abnormally distributed quantitative variables. In contrast, Kruskal-Wallis test was employed to compare different groups for abnormally distributed quantitative variables, followed by Post hoc test (Dunn’s for multiple comparisons test) for pairwise comparison. ANOVA was deployed to compare between more than two groups. Significance of the obtained results was judged at the 5% level [15, 16].
Table 3. Relation between menopausal status and different parameters.

| Menopausal          | Catechol-O-methyl transferase | 17β estradiol |
|---------------------|------------------------------|--------------|
|                     | Premenopausal | Postmenopausal | Premenopausal | Postmenopausal |
| Tissue              |               |               |               |               |
| Control group (n = 12) | (n = 8) | (n = 12) | (n = 8) | (n = 8) |
| Mean ± SD           | 528.3 ± 93.7 | 531.5 ± 51.5 | 11.23 ± 0.71 | 11.54 ± 0.71 |
| U (p)               | 40.50 (0.571) | 33.0 (0.270) | 10.500* (<0.001*) | 16.500* (0.001*) |
| Benign group (n = 23) | (n = 7) | (n = 23) | (n = 7) | (n = 7) |
| Mean ± SD           | 610.59 ± 121.85 | 783.66 ± 29.27 | 15.69 ± 1.09 | 13.58 ± 1.32 |
| U (p)               | 10.500* (<0.001*) | 16.500* (0.001*) | 28.0* (0.002*) | 25.0* (0.001*) |
| Malignant group (n = 21) | (n = 9) | (n = 21) | (n = 9) | (n = 9) |
| Mean ± SD           | 350.1 ± 47.6 | 471.5 ± 128.2 | 22.72 ± 5.85 | 17.57 ± 1.87 |
| U (p)               | 28.0* (0.002*) | 25.0* (0.001*) | 33.0* (0.004*) | 36.50* (0.007*) |
| Serum               |               |               |               |               |
| Control group (n = 12) | (n = 8) | (n = 12) | (n = 8) | (n = 8) |
| Mean ± SD           | 326.9 ± 17.0 | 318.1 ± 20.0 | 9.04 ± 1.07 | 8.21 ± 1.05 |
| U (p)               | 38.50 (0.473) | 27.0 (0.115) | 16.500* (0.001*) | 25.500* (0.005*) |
| Benign group (n = 23) | (n = 7) | (n = 23) | (n = 7) | (n = 7) |
| Mean ± SD           | 402.07 ± 123.49 | 715.49 ± 279.79 | 10.42 ± 1.96 | 8.20 ± 0.45 |
| U (p)               | 16.500* (0.001*) | 25.500* (0.005*) | 33.0* (0.004*) | 36.50* (0.007*) |
| Malignant group (n = 21) | (n = 9) | (n = 21) | (n = 9) | (n = 9) |
| Mean ± SD           | 337.6 ± 38.6 | 437.9 ± 109.2 | 14.75 ± 4.73 | 10.44 ± 4.05 |
| U (p)               | 33.0* (0.002*) | 36.50* (0.007*) | 10.500* (<0.001*) | 16.500* (0.001*) |

U, Mann Whitney test.
*, Statistically significant at p ≤ 0.05.

3. Results

3.1 Subjects’ demographic data

Age distributions and menstrual state among benign, malignant ovarian tumors and healthy control groups were studied. No statistically significant differences existed (p = 0.053, 0.452), respectively.

3.2 Pathological data

Most patients with benign tumors were benign ovarian cystadenoma (50%), while others were endometrioma (40%) and ovarian fibroma (10%). Patients with malignant tumors were serous adenocarcinoma (60%), endometroid adenocarcinoma (30%) and mucinous adenocarcinoma (10%). All patients with serous adenocarcinoma were of high grade.

3.3 Catechol-O-methyltransferase concentrations

COMT concentrations were measured in serum and ovarian tissues of all studied groups, as illustrated in Table 1. A significant increase in COMT level existed in tissue than in serum in all groups. Both tissue and serum levels of COMT in patients with malignant tumors were significantly lower than in control and benign groups (p < 0.001) for tissue and (p = 0.022, p = 0.001) for serum.

3.4 17β estradiol concentrations

17β estradiol concentrations were measured in serum and ovarian tissues of all studied groups, as illustrated in Table 2. A significant increase of 17β estradiol level existed in tissue than in serum. Both tissue and serum levels of 17β estradiol in patients with malignant tumors were significantly higher than in control and benign groups (p < 0.001) for tissue (p < 0.001, p < 0.003) for serum. Also, both tissue and serum levels of 17β estradiol were significantly decreased in postmenopausal females than in premenopausal females in patients with benign and malignant ovarian tumors, as illustrated in Table 3.

3.5 Correlation between Catechol-O-methyltransferase and 17β estradiol levels

A negative correlation was found between COMT and 17β estradiol levels in patients with benign and malignant ovarian tumors, as illustrated in Fig. 1.

4. Discussion

Ovarian cancer can be initiated by unbalanced estrogen metabolism leading to estrogen–DNA adducts that cause mutations in critical genes in the ovarian epithelial cells. In addition estrogen metabolism is strongly implicated in developing ovarian and other hormonal cancers [17]. Many risk factors associated with ovarian cancer development are related to estrogen exposure [18].

COMT enzyme catalyzes formation of reactive estrogen metabolites and DNA adducts. Moreover, it has been associated with ovarian cancer when combined with other polymorphisms in the catechol estrogen pathway [19].

This study aimed to evaluate a potential correlation between COMT and 17β estradiol levels and ovarian cancer.
Several studies have indicated that 17β-estradiol (E2) can increase the risk of epithelial ovarian cancer development by directly acting on OSE cells. When treated with E2, these cells are more susceptible to neoplastic transformation due to E2 ability to increase proliferation and production of reactive oxygen species in these cells [20–22].

According to our results, both tissue and serum levels of COMT were significantly decreased in patients with malignant ovarian tumors compared to benign and control groups. This inhibition in neoplastic tissues reflects the role of altered COMT activity in ovarian cancer development. In accordance with our results, Zahid et al. [17] concluded that estrogen metabolism was unbalanced and estrogen DNA adducts were significantly higher in women with ovarian cancer compared to control women without cancer (p < 0.0001). These results suggest that formation of estrogen—DNA adducts by COMT plays a critical role in ovarian cancer initiation [17].

In addition, Lavingie et al. [23] in a study on MCF-7 cells treated with E2 stated direct relationship between carcino- genic estrogen metabolites and oxidative DNA damage in the absence of COMT activity and O-methylated metabolites.

COMT inhibition in neoplastic tissue may reflect that this defect could be a primary impairment of COMT gene in patients with malignant ovarian tumors. In contrast, the absence of this inhibition in patients with benign ovarian tumors may reveal a protective effect of COMT gene against DNA damage and neoplastic transformation. This was in agreement with findings from different studies [10–14].

In accordance with our results, other studies concluded that polymorphism in COMT gene, which codes for a low activity variant of COMT enzyme, is associated with increased risk of breast cancer development [24–28].

In addition, our results demonstrated higher concentrations of 17β estradiol in ovarian tissues compared to serum samples in all studied groups with elevated tissue/serum ratio of 17β estradiol. This may indicate an essential role of ovarian tissues concentrations of estradiol in tumor biology. Besides, both tissue and serum levels of 17β estradiol in patients with malignant tumors were significantly higher than in control and benign groups. Consistent with our findings, Lavi-
Cavestri et al. [29] stated that exogenous 17β-estradiol (E2) accelerates ovarian cancer progression in the transgenic mouse model of disease. However, based on differences in concentrations of gonadal hormones between different ovarian tumor groups, postmenopausal women with ovarian tumors have decreased E2 tissue levels. In the malignant group, E2 levels were 17.14 pmol/L (15.58–21.84) and 19.85 pmol/L (17.32–34.15) in postmenopausal women and premenopausal women, respectively. In the benign group, E2 levels were 13.2 pmol/L (12.4–16.2) and 15.6 pmol/L (13.9–18) in postmenopausal women and premenopausal women, respectively. Therefore, our results were incoherent with Lindgren et al. [30], who suggested an increased production of gonadal hormones in ovarian cancer tissue of postmenopausal females.

Correlation analysis showed a negative correlation between COMT and 17β estradiol in tissue and serum of patients with benign and malignant ovarian tumors. This confirms that COMT enzyme holds a vital function in the decreased production of carcinogenic estrogen metabolites, and low COMT is associated with developing malignant ovarian tumors.

5. Conclusions

We can conclude that low COMT activity and high tissue/serum level of 17β estradiol may be contributory factors for ovarian cancer development, while the absence of COMT inhibition in benign group is protective against imbalance in estrogen homeostasis and neoplastic transformation. This corroborates the notion that targeting estrogen metabolism can be an alternative way to reduce ovarian cancer risk. We recommend additional mechanistic studies and perhaps developing an appropriate mouse model to provide more insights into the role of COMT activity and polymorphisms affecting their levels in ovarian tissue and ovarian cancer.

Abbreviations

FIGO, International federation of Obstetrics and Gynecology; COMT, Catechol-O-methyltransferase; CEs, catechol estrogen metabolites; MeOE2, methoxyestradiol dGdeoxyguanine; OSE, ovarian surface epithelium.

Author contributions

HN conceived and designed the study; NME collected the samples; EO carried out ELISA. EO, NME and NAE analyzed the data; HN and EO shared in writing the paper. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the Faculty of Medicine at Alexandria University. Informed written consent for patients’ participation in Clinical Research 2018 (serial number 0304867) was obtained from all participants before enrollment into the study.

Acknowledgment

We would like to express our gratitude to all those who helped us during the writing of this manuscript.

Funding

This research received no external funding.

Conflict of interest

The authors declare no conflict of interest.

Availability of data and materials

The raw data used and analyzed during the current study are available from the corresponding author on reasonable request.

References

[1] Choi J, Wong AST, Huang H, Leung PCK. Gonadotropins and ovarian cancer. Endocrine Reviews. 2007; 28: 440–461.
[2] Mungenast F, Thalhammer T. Estrogen biosynthesis and action in ovarian cancer. Frontiers in Endocrinology. 2014; 5: 192.
[3] Yager JD. Mechanisms of estrogen carcinogenesis: the role of E2/E1–quinone metabolites suggests new approaches to preventative intervention–a review. Steroids. 2015; 99: 56–60.
[4] Cavalieri EL, Rogan EG. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. Journal of Steroid Biochemistry and Molecular Biology. 2011; 125: 169–180.
[5] Chang CY, McDonnell DP. Molecular pathways: the metabolic regulator estrogen-related receptor α as a therapeutic target in cancer. Clinical Cancer Research. 2012; 18: 6089–6095.
[6] Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Letters. 2012; 324: 13–30.
[7] Petrie WK, Dennis MK, Hu C, Dai D, Arterburn JB, Smith HO, et al. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstetrics and Gynecology International. 2013; 2013: 1–17.
[8] Zhu BT, Liehr JG. Inhibition of the Catechol -O-methyltransferase-catalyzed O-methylation of 2- and 4-hydroxyestradiol by catecholamine: implications for the mechanism of estrogen-induced carcinogenesis. Archives of Biochemistry and Biophysics. 1993; 304: 248–256.
[9] Goodman JE, He P, Yager JD. Kinetics of human soluble high and low activity Catechol-O-methyltransferase catalyzed catechol estrogen methylation. Proceedings of the American Association for Cancer Research. 2001; 42: 883.
[10] Fotsis T, Zhang Y, Pepper MS, Adlereutz H, Montesano R, Nawroth PP, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994; 368: 237–239.
[11] Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, et al. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Molecular Pharmacology. 1997; 51: 951–962.
[12] Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Research. 1998; 58: 2269–2277.
[13] Parohit A, Hejaz HA, Walden L, MacCarth-y-Morrogh L, Packham G, Potter BV, et al. The effect of 2-methoxyoestron-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. International Journal of Cancer. 2000; 85: 584–589.
[14] MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HAM, Potter BVL, Reed MJ, et al. Differential effects of estrone and estrone-3-O-sulphamate derivatives on mitotic, Arrest, apoptosis,
and microtubule assembly in human breast cancer cells. Cancer Research. 2000; 60: 5441–5450.

[15] Kotz S, Balakrishnan N, Read CB, Vidakovic B, Johnson NL. Encyclopedia of statistical sciences. 2nd edn. Hoboken: Wiley-Interscience. 2006.

[16] Kirkpatrick LA, Feeney BC. A simple guide to IBM SPSS statistics for version 20.0. Student edn. Belmont: Wadsworth, Cengage Learning. 2013.

[17] Zahid M, Beseler CL, Hall JB, LeVan T, Cavalieri EL, Rogan EG. Unbalanced estrogen metabolism in ovarian cancer. International Journal of Cancer. 2014; 134: 2414–2423.

[18] Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clinical Obstetrics and Gynecology. 2012; 55: 3–23.

[19] Laviolette LA, Hodgkinson KM, Minhas N, Perez-Iratxeta C, Vanderhyden BC. 17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo. International Journal of Cancer. 2014; 135: 1072–1084.

[20] Bai W, Oliveros-Saunders B, Wang Q, Acevedo-Duncan ME, Nicosia SV. Estrogen stimulation of ovarian surface epithelial cell proliferation. In Vitro Cellular & Developmental Biology. Animal. 2001; 36: 657–666.

[21] Symonds DA, Merchenthaler I, Flaws JA. Methoxychlor and estradiol induce oxidative stress DNA damage in the mouse ovarian surface epithelium. Toxicological Sciences. 2008; 105: 182–187.

[22] Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, et al. 17beta-estradiol accelerates tumor onset and decreases survival in a transgenic mouse model of ovarian cancer. Endocrinology. 2010; 151: 929–938.

[23] Lavigne JA, Goodman JE, Fonong T, Odwin S, He P, Roberts DW, et al. The effects of Catechol -O- methyltransferase inhibition on estrogen metabolite and oxidative DNA damage levels in estradiol-treated MCF-7 cells. Cancer Research. 2001; 61: 7488–7494.

[24] Syed V, Ulinski G, Mok SC, Yiu GK, Ho SM. Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Research. 2001; 61: 6768–6776.

[25] Scanlon PD, Raymond FA, Weinshilboum RM. Catechol -O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science. 1979; 203: 63–65.

[26] Lachman HM, Paplos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human Catechol -O- methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996; 6: 243–250.

[27] Palmater MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different Catechol -O- methyltransferase alleles. Biological Psychiatry. 1999; 46: 557–567.

[28] Tolba MF, Omar HA, Harsi F, Nunes ACF, Noreddin AM. The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers. Molecular and Cellular Endocrinology. 2019; 488: 79–88.

[29] Laviolette LA, Garson K, Macdonald EA, Senterman MK, Courville K, Crane CA, et al. The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors. International Journal of Oncology. 2002; 21: 583–589.